SynthesisReproductive health2025
The impact of chronic hepatitis B and chronic hepatitis C on sexual function: a systematic review and meta-analysis.
Synthesis in Reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sexual dysfunction, depressive symptoms, and perceived impact of HBV infectivity among noncirrhotic patients with chronic hepatitis B: a cross-sectional study.Frontiers in public health · 2026Article
- Sexual dysfunction in chronic hepatitis B: a comprehensive review of pathophysiology, clinical burden, and integrated management.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionSeveral studies have identified an association between chronic hepatitis B (CHB), chronic hepatitis C (CHC), and an elevated risk of sexual dysfunction (SD). However, no systematic review or meta-analysis has been conducted to investigate this relationship.
objectiveThis study aimed to provide an overview of the prevalence of SD and its associated risk factors in patients with CHB and/or CHC.
methodsDatabases including EMBASE, MEDLINE, and the Cochrane Library, were systematically searched from their inception until June 14, 2023, to identify studies that reported SD in CHB and CHC patients. Subgroup analysis, meta-regression, and sensitivity analysis were employed to detect potential sources of bias.
resultsOut of 734 identified records, 18 studies (encompassing 2,898 patients, 77.6% of whom were men, with a mean age ranging from 36 to 59 years) were included to calculate the overall pooled prevalence of SD. The prevalence of SD was found to be 47.8% (95% CI: 33.9%-61.9%, I2 = 98.4%, p < 0.001) among patients with CHB and/or CHC. Subgroup analysis, meta-regression, and sensitivity analysis did not reveal any potential sources of bias. The prevalence of SD was 56.9% (95% CI: 40.1%-73.0%, I2 = 94.7%, p < 0.001) in women and 44.4% (95% CI: 28.1%-61.4%, I2 = 98.5%, p < 0.001) in men. Synthesis of the data showed that CHB and CHC were significantly associated with an increased risk of developing SD in both sexes (RR = 3.58, 95% CI: 2.76–4.66, I2 = 82.5%, p < 0.001). Hepatitis C virus (HCV) infection (OR: 4.30, 95% CI: 2.74–6.74, I2 = 0.0%, p = 0.397) and depression (OR: 1.51, 95% CI: 1.31–1.75, I2 = 48.3%, p < 0.001) were identified as risk factors for SD in men, and HCV infection (OR: 7.57, 95% CI: 4.16–13.77, I2 = 0.0%, p = 0.747) was also identified as a risk factor for SD in women.
conclusionThe prevalence of SD in patients with CHB and/or CHC is notably high, and the risk of SD increases in both male and female patients with CHB and CHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.